{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibodies+Bispecific&page=2", "query": { "condition": "Antibodies Bispecific", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antibodies+Bispecific&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T21:39:54.179Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05972135", "title": "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Oral Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-10-23", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 17, "location_summary": "Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05972135" }, { "nct_id": "NCT03321981", "title": "MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Zenocutuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Endocrine therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merus B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 105, "start_date": "2018-01-15", "completion_date": "2023-07-26", "has_results": true, "last_update_posted_date": "2024-03-07", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 3, "location_summary": "Los Angeles, California • Kansas City, Kansas • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321981" }, { "nct_id": "NCT06822972", "title": "HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse", "Multiple Myeloma, Refractory" ], "interventions": [ { "name": "Selinexor 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-08-22", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06822972" }, { "nct_id": "NCT06097364", "title": "A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "Odronextamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone/Prenisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 733, "start_date": "2023-11-14", "completion_date": "2029-07-29", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 9, "location_summary": "Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097364" }, { "nct_id": "NCT03860207", "title": "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma", "Osteosarcoma", "Other Solid Tumor Cancers" ], "interventions": [ { "name": "Humanized 3F8 Bispecific Antibody", "type": "BIOLOGICAL" }, { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Y-mAbs Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 12, "start_date": "2019-02-22", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860207" }, { "nct_id": "NCT04648202", "title": "FS120 Phase 1/1b Study in Patients With Advanced Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "FS120", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "invoX Pharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2020-11-18", "completion_date": "2026-03-01", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 4, "location_summary": "New Haven, Connecticut • Houston, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04648202" }, { "nct_id": "NCT05663866", "title": "Premedication to Reduce Amivantamab Associated Infusion Related Reactions", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Amivantamab", "type": "DRUG" }, { "name": "Lazertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2023-05-18", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 3, "location_summary": "Fountain Valley, California • Fairfax, Virginia • Renton, Washington", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Fairfax", "state": "Virginia" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05663866" }, { "nct_id": "NCT06976476", "title": "Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Hypogammaglobulinemia", "Hypogammaglobulinemia, Acquired" ], "interventions": [ { "name": "IgPro20", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-05-08", "completion_date": "2029-05-08", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06976476" }, { "nct_id": "NCT04889716", "title": "CAR-T Followed by Bispecific Antibodies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-cell Lymphoma", "DLBCL - Diffuse Large B Cell Lymphoma" ], "interventions": [ { "name": "mosunetuzumab", "type": "DRUG" }, { "name": "glofitamab", "type": "DRUG" }, { "name": "obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2021-11-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 2, "location_summary": "Omaha, Nebraska • Philadelphia, Pennsylvania", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04889716" }, { "nct_id": "NCT07195916", "title": "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Hematologic Malignancies" ], "interventions": [ { "name": "INCA036873", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2026-01-08", "completion_date": "2028-08-18", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-26T21:39:54.179Z", "location_count": 8, "location_summary": "Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195916" } ] }